Nanolive hosts this event on “Non-invasive, high content live cell assays to increase translational relevance of in vitro drug development of biologics and small molecules”.
In this webinar, we present the following use-cases of our immuno-oncology and cytotoxicity assays from industry-leading biopharma companies to test toxicity, selectivity, uptake and expression of different targeted therapies.
- Immune cell therapeutics:
- Bispecific antibody screening in a T cell-target cell co-culture (Light Chain Bioscience)
- Drug selectivity and cytotoxicity:
- mRNA expression and cytotoxicity (TRON)
- Drug selectivity in co-cultures: senolytics (dsm-firmenich)
- Measuring particle uptake (bit.bio)
This webinar lasts 20 to 25 minutes.
Read our latest news
Revolutionizing lipid droplet analysis: insights from Nanolive’s Smart Lipid Droplet Assay Application Note
Introducing the Smart Lipid Droplet Assay: A breakthrough in label-free lipid droplet analysis Discover the power of Nanolive's Smart Lipid Droplet Assay (SLDA), the first smart digital assay to provide a push-button solution for analyzing lipid droplet dynamics,...
Food additives and gut health: new research from the University of Sydney
The team of Professor Wojciech Chrzanowski in the Sydney Pharmacy School at the University of Sydney have published their findings on the toxic effect of titanium nanoparticles found in food. The paper “Impact of nano-titanium dioxide extracted from food products on...
2023 scientific publications roundup
2023 has been a record year for clients using the Nanolive system in their scientific publications. The number of peer-reviewed publications has continued to increase, and there has been a real growth in groups publishing pre-prints to give a preview of their work....
